|FOR IMMEDIATE RELEASE
October 22, 1998
Toyama Chemical & Eisai Sign Co-development Licensing Agreement in Japan for Toyama is T-614, a New Treatment for Rheumatoid Arthritis Currently Under Development in Japan and in Foreign Countries
|Toyama Chemical Co., Ltd.|
|2-5, Nishishinjuku, 3-chome|
|Shinjuku-ku, Tokyo, Japan|
|Eisai Co., Ltd.|
|6-10, Koishikawa 4-chome|
|Bunkyo-ku, Tokyo, Japan|
Toyama Chemical Co., Ltd. (President: Katsuhiko Nakano) and Eisai Co., Ltd. (President: Haruo Naito) signed an agreement for the co-development and co-marketing of T-614 in Japan on September 30. T-614 is an anti-rheumatic agent currently under development by Toyama in Japan (Phase III
) and in the United Kingdom (in preparations for initiation of Phase II
- Toyama and Eisai shall co-develop T-614 in Japan from Phase III studies and co-submit the marketing application to the Japanese Ministry of Health and Welfare
- Both companies will co-market T-614 in Japan
- After approval Toyama will supply the bulk substance or the semi-finished product with Eisai conducting packaging for Eisai marketing
<Information Concerning T-614>
- Current Status of Anti-rheumatic Agents
Chronic Rheumatoid Arthritis (RA) is a chronic inflammatory disease and disorder of the immune system that causes articular destruction and malformation, and functional disability.
Currently in Japan patients suffering from RA are treated with disease modifying anti-rheumatic drugs (DMARDs) from the early stages of the disease. However, the available treatments often have side effects and varying rates of efficacy among patients. Toyama Chemical is now conducting clinical trials of T-614, a new treatment for rheumatoid arthritis with the aim of fewer side effects and greater efficacy. T-614 is currently in Phase III clinical trials in Japan and preparations are underway for the initiation of Phase IIa clinical trials in the United Kingdom.
- Clinical Trial Characteristics of T-614
- T-614 has shown a significant decrease in various inflammatory diagnostic parameters such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) and in immunoglobins
- T-614 demonstrated in clinical trials in RA, a very high rate of efficacy compared with currently available DMARDs and a high safety profile
- T-614 has shown a rapid onset of efficacy and is expected to be effective for patients who have not responded to other DMARDs treatments
- T-614 Characteristics
- T-614 has a new chemical structure in which a methylsulfonylamino group is introduced into a chromone chemical structure.
- T-614 has shown improved effects on articular lesions and immunological abnormalities in animal models of chronic arthritis and autoimmune diseases.
- T-614 suppresses the production of inflammatory cytokines (IL-1, IL-6, IL-8, and TNF (tumor necrosis factor)).
- T-614 inhibits lymphocyte proliferation and immunoglobin production.
- For Further Information:
|General Affairs Division, Public Relations Department,
|Toyama Chemical Co., Ltd.
|Public Relations & Legal Division, Public Relations Group,
|Eisai Co., Ltd.